98.31
0.07 (0.07%)
| Penutupan Terdahulu | 98.24 |
| Jumlah Dagangan | 691,882 |
| Harga / Pendapatan (P/E Ke hadapan) | 526.32 |
| Harga / Jualan (P/S) | 27.61 |
| Harga / Buku (P/B) | 65.68 |
| Julat 52 Minggu |
| Margin Keuntungan | -123.28% |
| Margin Operasi (TTM) | -143.73% |
| EPS Cair (TTM) | -2.80 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 25.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 69.65% |
| Nisbah Semasa (MRQ) | 3.30 |
| Aliran Tunai Operasi (OCF TTM) | -113.49 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -96.71 M |
| Pulangan Atas Aset (ROA TTM) | -51.33% |
| Pulangan Atas Ekuiti (ROE TTM) | -150.20% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Rhythm Pharmaceuticals, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.63 |
|
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.65% |
| % Dimiliki oleh Institusi | 103.78% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Ra Capital Management, L.P. | 30 Jun 2026 | 6,666,837 |
| Baker Bros. Advisors Lp | 30 Jun 2026 | 5,604,483 |
| Primecap Management Co/Ca/ | 30 Jun 2026 | 3,168,853 |
| Jpmorgan Chase & Co | 30 Jun 2026 | 2,652,746 |
| Price T Rowe Associates Inc /Md/ | 30 Jun 2026 | 2,566,171 |
| Federated Hermes, Inc. | 30 Jun 2026 | 1,785,716 |
| Polar Capital Holdings Plc | 30 Jun 2026 | 1,663,632 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| MEEKER DAVID P | - | 102.44 | -50,000 | -5,122,000 |
| Jumlah Keseluruhan Kuantiti Bersih | -50,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -5,122,000 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 102.44 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| MEEKER DAVID P | Pegawai | 14 Sep 2026 | Jual automatik (-) | 50,000 | 102.44 | 5,122,000 |
| MEEKER DAVID P | Pegawai | 14 Sep 2026 | Pelaksanaan pilihan | 50,000 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |